Alefacept

Simple item page
dc.contributor.authorŞahin M.T.
dc.date.accessioned2024-07-22T08:22:46Z
dc.date.available2024-07-22T08:22:46Z
dc.date.issued2007
dc.description.abstractAlefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented. © 2007 Bentham Science Publishers Ltd.
dc.identifier.DOI-ID10.2174/187152307781368229
dc.identifier.issn18715230
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19229
dc.language.isoEnglish
dc.subjectalefacept
dc.subjectcalcipotriol
dc.subjectimmunosuppressive agent
dc.subjectplacebo
dc.subjectsteroid
dc.subjectalopecia areata
dc.subjectautoimmune disease
dc.subjectcapillary leak syndrome
dc.subjectchill
dc.subjectclinical trial
dc.subjectcommon cold
dc.subjectdisease severity
dc.subjectdrug cost
dc.subjectdrug efficacy
dc.subjectdrug fever
dc.subjectdrug induced headache
dc.subjectdrug mechanism
dc.subjectdrug safety
dc.subjectdrug withdrawal
dc.subjecthuman
dc.subjectimmune deficiency
dc.subjectimmunogenicity
dc.subjectinfection risk
dc.subjectinjection site reaction
dc.subjectlichen planus
dc.subjectlow drug dose
dc.subjectmaintenance therapy
dc.subjectmalignant neoplastic disease
dc.subjectmemory T lymphocyte
dc.subjectmonotherapy
dc.subjectopportunistic infection
dc.subjectpatient information
dc.subjectpharmacodynamics
dc.subjectphototherapy
dc.subjectpsoriasis
dc.subjectquality of life
dc.subjectremission
dc.subjectreview
dc.subjectside effect
dc.subjectsingle drug dose
dc.subjectT lymphocyte activation
dc.subjectultraviolet B radiation
dc.titleAlefacept
dc.typeReview

Files

Collections

Scopus Koleksiyonu